Top in hem/onc: CAR T-cell therapy, racial bias in cancer care
Click Here to Manage Email Alerts
Chimeric antigen receptor T-cell therapy weakens the immune system, leaving the recipient vulnerable to infection. An in-depth look at the infection risk associated with this treatment was the top story in hematology/oncology last week.
Another top story was about new recommendations from the National Comprehensive Cancer Network (NCCN), American Cancer Society Cancer Action Network and National Minority Quality Forum that aim to reduce racial bias in cancer care.
Read these and more stories in hematology/oncology below:
‘On-your-toes’ approach to managing infection risk needed as CAR T-cell therapy evolves
In this article, Joshua A. Hill, MD, discusses the risk for infection among patients receiving chimeric antigen receptor T-cell therapy and provides practical advice for clinicians about prevention and mitigation strategies. Read more.
Recommendations seek to reduce racial bias in cancer care
Robert W. Carlson, MD, CEO of NCCN, spoke with Healio about a series of recommendations that were developed to improve equity in cancer care and the steps necessary to put the recommendations into practice. Read more.
Acupuncture techniques reduce chronic pain among cancer survivors
Electroacupuncture and auricular acupuncture led to greater pain reductions than usual care among cancer survivors with chronic musculoskeletal pain, according to results of a randomized clinical trial published in JAMA Oncology. Read more.
Regular consumption of sugar-sweetened soda increases risk for breast cancer mortality
Regular consumption of sugar-sweetened soda appeared to be associated with an increased risk for death among women with breast cancer, according to study findings published in Cancer Epidemiology, Biomarkers & Prevention. Read more.
FDA plans public meeting to reevaluate accelerated approvals of cancer drugs
FDA’s Oncologic Drugs Advisory Committee plans to hold a public meeting April 27-29 to review six indications for cancer drugs that were granted accelerated approval but subsequently failed to show clinical benefit in confirmatory trials. Read more.